Exactly, most BP only have failed NASH trials so far and either no NASH pipeline left or only early stage candidates. I haven’t researched the field recently, but recall ICPT, GALT and VKTX with the most promising late stage pipeline drugs still standing.....and GILD drug failed earlier this year.
$100,000 spent to get an extremely drug to phase 2 in NASH could end with an extremely lucrative ROI in the future.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.